Highest-materiality recent filing
GT Biopharma receives Nasdaq extension to Nov 16, 2026 to meet $1 minimum bid price
Received Nasdaq Staff letter on May 20, 2026 granting 180-day extension until Nov 16, 2026 for minimum bid price compliance.
GT Biopharma enters agreement with Univ. of Minnesota for Phase 1a/1b trial of GTB-5550
Agreement for IND 169118 GTB-5550 (camB7-H3 TriKE) in advanced solid tumors that failed prior therapy.
GT Biopharma restates Q2/Q3 2025 financials; Greenshoe Rights liability misclassified
Audit committee concluded non-reliance on Q2 and Q3 2025 Form 10-Q after finding Greenshoe Rights should have been liability under ASC 480.
GT Biopharma receives Nasdaq delisting notice for low bid price
Nasdaq notified GT Biopharma on Nov 20, 2025 that stock closed below $1 for 30 consecutive days, violating Minimum Bid Price Requirement.
Private placement of up to 6,056 shares of Series L 10% Convertible Preferred Stock at $1,000 stated value; net proceeds $5.45M.
GT Biopharma doses first patient in Phase 1 trial of GTB-3650 for hematologic malignancies
GTB-3650 is a second-generation TriKE using camelid nanobody technology to improve potency and binding affinity.
GT Biopharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M minimum
Nasdaq letter on Nov 21, 2024: stockholders' equity fell below $2.5M required for continued listing.
GT Biopharma enters Phase 1 clinical trial agreement with U of Minnesota for GTB-3650 in MDS/AML
Agreement for investigator-initiated Phase 1 trial of GTB-3650 (CD16/IL-15/CD33 TriKE) in high-risk MDS, relapsed/refractory AML, MRD.
GT Biopharma receives FDA clearance for IND of GTB-3650; Phase 1 trial to start H2 2024
FDA cleared IND for GTB-3650, an NK cell engager for CD33+ leukemias; Phase 1 trial initiation expected H2 2024.
GT Biopharma submits IND to FDA for GTB-3650 for CD33+ leukemia
IND submitted for GTB-3650, a 2nd generation nanobody TriKE targeting CD33+ leukemia (relapsed/refractory AML and high-risk MDS).
GT Biopharma gets Nasdaq extension to Feb 20, 2024 for bid price compliance
Company has until Feb 20, 2024 to close at $1.00 for 10 consecutive days to regain compliance.
GT Biopharma receives Nasdaq deficiency notice for bid price below $1.00 per share
Received Nasdaq deficiency letter on Feb 22, 2023; stock closed below $1.00 for 30 consecutive business days.
GT Biopharma raises $6.5M in registered direct offering of shares and warrants at $1.00 per unit
Offering of 6.5M shares or pre-funded warrants plus 6.5M warrants to purchase common stock.
GT Biopharma announces departure of President of R&D and CMO Gregory Berk
Dr. Gregory Berk no longer employed as President of R&D and Chief Medical Officer effective December 8, 2022.
GT Biopharma settles $6.5M Cytovance debt with stock and cash; aims for IND filings by Mar/Jun 2023
Issued 1,222,281 shares to Cytovance to settle $3.25M of invoices; will pay another $3.25M in cash over three months.
GT Biopharma names Michael Breen Interim CEO; Gregory Berk becomes President R&D/CMO
Michael Breen named Interim CEO effective March 2, 2022; base compensation raised to $515,000.
GT Biopharma appoints Manu Ohri as CFO, replacing Gavin Choy as Acting CFO
Manu Ohri appointed CFO effective Feb 14, 2022; Gavin Choy ceases as Acting CFO.
GT Biopharma fails Nasdaq independent director rule; cure until Nov 2022
Received Nasdaq notice on Nov 23, 2021 for non-compliance with Listing Rule 5605 after appointing Michael Breen as Executive Chairman.
On June 10, 2025, the Board appointed David C. Mun-Gavin as a non-employee director of the Board.
On June 9, 2025, Andrew Ritter resigned as a member of the board of directors (the “Board”) of the Company and all committees thereof.
appointed Hilary Kramer as a non-employee director to fill the vacancy created by the increase in the size of the Board
appointed Andrew Ritter as a non-employee director to fill one of the vacancies on the Board.
Bruce Wendel resigned as a member of the Board and all committees thereof.
Rajesh Shrotriya resigned as a member of the Board and all committees thereof.
On April 29, 2025, GT Biopharma, Inc. (the “Company”) appointed Michael Breen as its Chief Executive Officer for a two-year term, effective as of April 29, 2025.
Effective September 16, 2024, Dr. Jeffrey Miller ceased serving as the Registrant’s Consulting Chief Medical Officer and Consulting Chief Scientific Officer and commenced service as the Registrant’s Consulting Senior Medical Director.
In connection with Mr. Ohri’s termination, on June 3, 2024, the Company has appointed Alan L. Urban as the Company’s Chief Financial Officer.
On June 3, 2024, Manu Ohri’s employment as Chief Financial Officer at GT Biopharma, Inc. (the “Company”) was terminated.
the Registrant’s Board appointed Charles J. Casamento to fill a vacant seat on the Board
On May 1, 2023 Alan Urban resigned as a member of the Registrant’s Board of Directors (the “Board”).
Max materiality 0.90 · Median 0.50 · Most common event other_material